How Does Omalizumab (Xolair) Work for Chronic Urticaria?

Omalizumab, sold under the brand name Xolair, is a biologic medication that can substantially reduce symptoms for many people with chronic spontaneous urticaria (CSU). While daily antihistamines work primarily by blocking the effects of histamine after it is released, omalizumab acts further upstream. It reduces the immune signaling that activates your cells, which can lower the likelihood and severity of hives and itching ^[1][2].

How Omalizumab Works

To understand how omalizumab works, it helps to look at the immune cells involved. In CSU, immune cells in your skin (mast cells) and blood (basophils) release histamine and other inflammatory chemicals ^[3].

In many patients, these cells are activated by a type of antibody called IgE. Omalizumab is an antibody made in a lab designed to find and bind to free-floating IgE in your bloodstream ^[1]. By capturing this IgE, omalizumab prevents it from attaching to the receptors on your mast cells and basophils, which reduces their reactivity and prevents them from dumping histamine into your skin ^[2][3].

Note: CSU is biologically complex and “spontaneous” means there is usually no external allergy trigger. While we can think of IgE as the “spark” and histamine as the “fire” as a simplified analogy, omalizumab is not treating a food or environmental allergy, and it does not guarantee zero hives for everyone ^[4].

Dosing and the Treatment Ladder

Omalizumab is generally considered a “Step 3” treatment. This means it is typically prescribed after a clinician-guided trial of modern, non-sedating H1 antihistamines at increased doses has not provided enough relief. (You should never increase antihistamine doses or combine medications without your doctor’s supervision.)

For CSU, the approved dose in the United States is generally 150 mg or 300 mg given by subcutaneous (under the skin) injection every 4 weeks ^[5]. The 300 mg dose is often delivered as two separate injections during the same visit. Your prescriber will determine the right dose for you.

How Well Does It Work?

Omalizumab is highly effective for many patients. In major clinical trials using the 300 mg dose over 12 weeks:

• About 52% to 66% of patients achieved “well-controlled” disease, defined by a specific clinical measure (a Urticaria Activity Score over 7 days, or UAS7, of 6 or less) ^[5].
• About 34% to 44% achieved a “complete response” (a UAS7 of 0, meaning absolutely no hives or itching during the measurement period) ^[5].

In real-world observational studies—which include broader patient populations and different definitions of success—some researchers estimate complete response rates up to 72% ^[6]. However, these are group results, not a permanent cure or a guarantee of your individual outcome. Hives can return if the medication is reduced or stopped ^[7].

When Will I See Results?

Response times vary widely from person to person. While some patients notice improvement within the first 1 to 4 weeks, it usually takes longer for the medication to reach its full effect ^[5][8].

In clinical trials, the median time to reach well-controlled disease was about 6 weeks, and the median time to complete response was 12 to 13 weeks ^[5]. Waiting several weeks while still itching can be difficult, but lack of a dramatic response after the first injection does not mean the treatment has failed.

Continue taking your prescribed antihistamines unless your clinician advises otherwise. Clinicians typically wait 3 to 4 months before fully assessing whether omalizumab is working for you.

Administration, Safety, and Side Effects

How it is given:
Initially, injections are administered in a medical office. Depending on local protocols, your country’s guidelines, and your clinician’s assessment, you may later qualify for home self-administration. If you self-inject, you will receive training on how to do so safely and how to recognize severe reactions.

Anaphylaxis Risk:
There is a rare but serious risk of anaphylaxis, a severe, potentially life-threatening allergic reaction to the medication itself ^[9]. This can happen minutes, hours, or even days after the first dose or any subsequent dose ^[10]. For this reason, clinic protocols often require you to stay for an observation period after your injection ^[11].

If you experience warning signs of anaphylaxis—such as trouble breathing, swelling of the throat or tongue, faintness, severe dizziness, wheezing, or rapidly worsening widespread hives—use your prescribed emergency medicine (like an epinephrine auto-injector) and seek emergency medical care immediately ^[10]. (Note: Severe swelling of the tongue or throat is always an emergency, regardless of the cause).

Common Side Effects:
In CSU studies, adverse events are generally mild ^[12]. The most frequently reported side effects include:

• Headaches ^[13][14]
• Redness, swelling, or pain at the injection site ^[13]
• Asthenia (weakness or fatigue) and vertigo ^[13]

Long-Term Safety:
Available clinical and long-term observational data have not shown a clear increase in overall cancer risk with omalizumab, though observational studies always have some limitations ^[15].